RxDoctor Payments DataLook up a doctor →

Daniel Katselnik, MD

Endocrinology, Diabetes & Metabolism · Shavano Park, TXNPI 1861674855

Payments from drug & device makers

$1,218,616in general payments, 2019–2025

Across 2,239 payments — averaging $544.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$325K
  • Dexcom, Inc.$259K
  • Ascendis Pharma Endocrinology Inc$203K
  • Sanofi US Services Inc.$154K
  • CSL Behring$80K
  • Sanofi-aventis U.S. LLC$66K
  • plus $130K from 54 others
$110,005in research payments, 2019–2025

Across 6 payments — averaging $18,334 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dexcom, Inc.$110K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk590$325,239
Dexcom, Inc.155$259,087
Ascendis Pharma Endocrinology Inc19$203,262
Sanofi US Services Inc.18$154,311
CSL Behring45$80,126
Sanofi-aventis U.S. LLC118$65,554
AstraZeneca(2 entities)186$48,028
Boehringer Ingelheim85$17,397
Alnylam Pharmaceuticals Inc.3$15,479
Lilly USA, LLC129$10,890
Bayer20$10,311
Siemens Medical Solutions USA, Inc.5$6,455
Mannkind Corporation118$5,368
Insulet Corporation63$3,413
Amgen106$1,393
Sequel Med Tech, LLC24$863
AbbVie49$759
Antares Pharma, Inc.54$685
Abbott40$680
Amarin Pharma, Inc.42$653
Novartis29$555
Cequr Corporation4$524
Corcept Therapeutics29$494
Recordati_rare_diseases_inc.13$423
Xeris Pharmaceuticals, Inc.19$385
Tersera Therapeutics LLC1$380
Sanofi3$362
Sentynl Therapeutics, Inc.1$350
Ascensia Diabetes Care US Inc.5$311
Tandem Diabetes Care, Inc.12$267
Zealand Pharma US, Inc.14$262
Amneal Pharmaceuticals LLC15$255
EUSA Pharma (US) LLC7$214
Radius Health, Inc.11$181
Nevro Corp.3$179
Eisai Inc.10$177
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$158
Esperion Therapeutics, Inc.14$157
Kyowa Kirin, Inc.8$154
Medtronic(2 entities)6$148
Shire North American Group Inc9$148
Ipsen Biopharmaceuticals, Inc8$144
Madrigal Pharmaceuticals9$141
Johnson & Johnson9$135
Vivus LLC9$133
Valeritas, Inc.9$120
GRT US Holding, Inc.5$116
Nalpropion Pharmaceuticals LLC8$112
Intuity Medical Inc7$107
BETA Bionics, Inc.4$103
Echosens North America, Inc.1$99
Merck7$96
Clarus Therapeutics Inc.6$88
Currax Pharmaceuticals LLC6$87
Shield Therapeutics Inc5$82
Acerus Pharmaceuticals Corporation6$80
Averitas Pharma Inc.4$78
Soleno Therapeutics, Inc.3$73
IBSA Pharma Inc.5$72
Amphastar Pharmaceuticals, Inc.4$71

How this compares

$1,218,616 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$389,076
Medicare patients
504
Services billed
5,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Shavano Park

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →